Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385554246> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4385554246 abstract "<div>Abstract<p>Background: Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a cytotoxic maytansinoid payload. In a Phase 1 dose-escalation study, the maximum tolerated dose (MTD) was 100 mg/m<sup>2</sup> every 2 weeks (Q2W). Here we report results for two alternative schedules. Patients and methods: Adults aged ≥ 18 years (range 34–73) with locally advanced/metastatic solid tumors (N=43; colon/rectum, 29; stomach, 7; pancreas, 4; other, 3) expressing/likely to express CEACAM5 received intravenous tusamitamab ravtansine 120–170 mg/m<sup>2</sup> (loading dose [LD]), then 100 mg/m<sup>2</sup> Q2W (Q2W-LD, N=28), or 120–190 mg/m<sup>2</sup> fixed dose (Q3W, N=15). The primary endpoint was dose-limiting toxicities (DLTs) during Cycles 1–2 (Q2W-LD) and Cycle 1 (Q3W). Results: Reversible DLTs were observed in 2/9 patients (Grade 2 keratopathy; Grade 2 keratitis) with 170 mg/m<sup>2</sup> in Q2W-LD and in 2/3 patients (Grade 2 keratopathy; Grade 3 transaminase elevation) with 190 mg/m<sup>2</sup> in Q3W. Nineteen (67.9%) patients in Q2W-LD and 13 (86.7%) patients in Q3W experienced treatment-related adverse events (AEs); 3/43 patients discontinued treatment because of AEs. The most common AEs were asthenia, gastrointestinal complaints, keratopathy, keratitis, and peripheral sensory neuropathy. In this small, heavily pretreated population, no confirmed responses were observed; however, stable disease occurred in 35.7% of patients in Q2W-LD and 40.0% of patients in Q3W. Conclusions: Tusamitamab ravtansine had a favorable safety profile with both alternative administration schedules; MTDs were 170 mg/m<sup>2</sup> (LD) followed by 100 mg/m<sup>2</sup> Q2W, and 170 mg/m<sup>2</sup> Q3W as a fixed dose. [NCT02187848]</p></div>" @default.
- W4385554246 created "2023-08-04" @default.
- W4385554246 creator A5001478188 @default.
- W4385554246 creator A5004217317 @default.
- W4385554246 creator A5015190461 @default.
- W4385554246 creator A5019728767 @default.
- W4385554246 creator A5023804337 @default.
- W4385554246 creator A5026959613 @default.
- W4385554246 creator A5041145711 @default.
- W4385554246 creator A5050684671 @default.
- W4385554246 creator A5064446554 @default.
- W4385554246 creator A5085952795 @default.
- W4385554246 date "2023-08-03" @default.
- W4385554246 modified "2023-10-05" @default.
- W4385554246 title "Data from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens" @default.
- W4385554246 doi "https://doi.org/10.1158/2767-9764.c.6773851.v1" @default.
- W4385554246 hasPublicationYear "2023" @default.
- W4385554246 type Work @default.
- W4385554246 citedByCount "0" @default.
- W4385554246 crossrefType "posted-content" @default.
- W4385554246 hasAuthorship W4385554246A5001478188 @default.
- W4385554246 hasAuthorship W4385554246A5004217317 @default.
- W4385554246 hasAuthorship W4385554246A5015190461 @default.
- W4385554246 hasAuthorship W4385554246A5019728767 @default.
- W4385554246 hasAuthorship W4385554246A5023804337 @default.
- W4385554246 hasAuthorship W4385554246A5026959613 @default.
- W4385554246 hasAuthorship W4385554246A5041145711 @default.
- W4385554246 hasAuthorship W4385554246A5050684671 @default.
- W4385554246 hasAuthorship W4385554246A5064446554 @default.
- W4385554246 hasAuthorship W4385554246A5085952795 @default.
- W4385554246 hasBestOaLocation W43855542462 @default.
- W4385554246 hasConcept C112705442 @default.
- W4385554246 hasConcept C121608353 @default.
- W4385554246 hasConcept C126322002 @default.
- W4385554246 hasConcept C197934379 @default.
- W4385554246 hasConcept C2777288759 @default.
- W4385554246 hasConcept C2777387746 @default.
- W4385554246 hasConcept C71924100 @default.
- W4385554246 hasConcept C90924648 @default.
- W4385554246 hasConceptScore W4385554246C112705442 @default.
- W4385554246 hasConceptScore W4385554246C121608353 @default.
- W4385554246 hasConceptScore W4385554246C126322002 @default.
- W4385554246 hasConceptScore W4385554246C197934379 @default.
- W4385554246 hasConceptScore W4385554246C2777288759 @default.
- W4385554246 hasConceptScore W4385554246C2777387746 @default.
- W4385554246 hasConceptScore W4385554246C71924100 @default.
- W4385554246 hasConceptScore W4385554246C90924648 @default.
- W4385554246 hasLocation W43855542461 @default.
- W4385554246 hasLocation W43855542462 @default.
- W4385554246 hasOpenAccess W4385554246 @default.
- W4385554246 hasPrimaryLocation W43855542461 @default.
- W4385554246 hasRelatedWork W1964391114 @default.
- W4385554246 hasRelatedWork W1990335353 @default.
- W4385554246 hasRelatedWork W2051764329 @default.
- W4385554246 hasRelatedWork W2065005216 @default.
- W4385554246 hasRelatedWork W2089699421 @default.
- W4385554246 hasRelatedWork W2154372624 @default.
- W4385554246 hasRelatedWork W2377624422 @default.
- W4385554246 hasRelatedWork W2585977673 @default.
- W4385554246 hasRelatedWork W2803203200 @default.
- W4385554246 hasRelatedWork W3032237923 @default.
- W4385554246 isParatext "false" @default.
- W4385554246 isRetracted "false" @default.
- W4385554246 workType "article" @default.